STOCK TITAN

VolitionRx turns $250K and $215K notes into stock

VolitionRx Limited disclosed note conversions into equity for Lind Global Asset Management XII LLC under securities law exemptions.

(Moderate)
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

VolitionRx Limited (VNRX) reported unregistered equity issuances related to conversions of its senior secured convertible promissory notes held by Lind Global Asset Management XII LLC. On September 2, 2026, the company issued 706,214 shares of common stock to satisfy a $250,000 conversion obligation. On September 10, 2026, it issued an additional 707,236 shares of common stock to satisfy a $215,000 conversion obligation. These issuances were made to an existing securityholder in reliance on exemptions from registration under the Securities Act, without commissions, public offering, or general solicitation. As of September 14, 2026, common shares issued and outstanding totaled 27,903,326.

Positive

  • None.

Negative

  • None.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Conversion amount (September 2, 2026) $250,000 Principal converted into 706,214 common shares for Lind Global Asset Management XII LLC
Shares issued (September 2, 2026) 706,214 shares Common stock issued to satisfy a $250,000 conversion obligation
Conversion amount (September 10, 2026) $215,000 Principal converted into 707,236 common shares for Lind Global Asset Management XII LLC
Shares issued (September 10, 2026) 707,236 shares Common stock issued to satisfy a $215,000 conversion obligation
Shares outstanding 27,903,326 shares Common stock issued and outstanding as of September 14, 2026
Original note principal amounts $7,500,000 and $2,400,000 Principal of senior secured convertible promissory notes issued to Lind Global Asset Management XII LLC
senior secured convertible promissory notes financial
"issued to Lind senior secured convertible promissory notes in the original principal amounts"
Section 3(a)(9) regulatory
"in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2)"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
Section 4(a)(2) regulatory
"in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506 of Regulation D regulatory
"and/or Rule 506 of Regulation D under the Securities Act"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
blue sky laws regulatory
"and corresponding provisions of state securities or “blue sky” laws"
State-level securities laws that require companies and investment products to register, disclose key information, or meet exemptions before being sold to residents; they act like local consumer protection rules for investments. They matter to investors because they reduce the risk of fraud, ensure basic disclosure about what is being offered, and can affect where and how easily an investment can be bought or sold—similar to how building codes affect whether a house can be advertised in a neighborhood.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity transactions did VNRX report in this Form 8-K?

VolitionRx Limited reported issuing 706,214 shares on September 2, 2026 for a $250,000 note conversion and 707,236 shares on September 10, 2026 for a $215,000 note conversion, both to Lind Global Asset Management XII LLC.

How many VNRX shares were outstanding after these conversions?

As of September 14, 2026, VolitionRx Limited had 27,903,326 shares of common stock issued and outstanding, reflecting the effect of the reported note conversion issuances.

Who received the newly issued VNRX shares from the note conversions?

The newly issued shares were issued to Lind Global Asset Management XII LLC, an existing securityholder that held senior secured convertible promissory notes of VolitionRx Limited.

What exemptions from registration did VNRX rely on for these share issuances?

The share issuances were made in reliance on Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D, along with corresponding state “blue sky” law provisions.

Did VNRX pay commissions or conduct a public offering for these share issuances?

No. VolitionRx Limited stated that the issuances involved no paid commissions, did not involve a public offering, and were made without general solicitation or general advertising.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 9, 2026

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36833

 

91-1949078

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification Number)

 

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and zip code)

 

+1 (512) 774-8930

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed from last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock, par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities

 

Conversions of Notes

 

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”), senior secured convertible promissory notes in the original principal amounts of $7,500,000 and $2,400,000. In connection with its obligations under such notes, (a) on September 2, 2026 the Company issued to Lind an aggregate of 706,214 shares of common stock to satisfy a $250,000 conversion obligation, and (b) on September 10, 2026 the Company issued to Lind an aggregate of 707,236 shares of common stock to satisfy a $215,000 conversion obligation. The offering and sale of the shares of common stock underlying the notes were made in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 of Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The issuance of the shares of common stock was to an existing securityholder, did not involve any paid commissions, did not involve a public offering and was made without general solicitation or general advertising.

 

Outstanding Shares

 

As of September 14, 2026, there were 27,903,326 shares of the Company’s $0.001 par value common stock issued and outstanding.

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

VOLITIONRX LIMITED

Date: September 15, 2026

By:

/s/ Cameron Reynolds

Cameron Reynolds

Chief Executive Officer & President

 

 
3

Filing Exhibits & Attachments

5 documents

Keep reading